Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR-a) agonist known to
improve diabetic dyslipidemia, has been proposed as a drug to prevent cardiovascular disease
(CVD) in type 2 diabetes (T2D). However, the results of clinical trials have been mixed.
Supporting the hypothesis that these disappointing results hide a genetic heterogeneity in
the CVD response to fenofibrate, a common genetic variant (rs6008845) in the gene coding for
PPAR-a has been found to dramatically influence the ability of this drug to reduce CVD events
in the ACCORD Lipid trial (PMID:31974142).
The aim of this study is to validate these findings by dissecting the pathways and mechanism
through which this variant exerts such a modulatory effect, by means of a randomized clinical
trial.
If successful, this project will pave the way to a precision medicine approach to prescribe
fenofibrate optimally, offering a cardio-protective drug to those patients that are most
likely to experience a robust benefit from this medication.